Literature DB >> 18640080

Chylomicron amyloid-beta in the aetiology of Alzheimer's disease.

R Takechi1, S Galloway, M M S Pallebage-Gamarallage, J C L Mamo.   

Abstract

Alzheimer's disease is characterized by inflammatory proteinaceous deposits comprised principally of the protein amyloid-beta (Abeta). Presently, the origins of cerebral amyloid deposits are controversial, though pivotal for the prevention of Alzheimer's disease. Recent evidence suggests that in blood, Abeta may serve as a regulating apoprotein of the triglyceride-rich-lipoproteins and we have found that the synthesis of Abeta in enterocytes and thereafter secretion as part of the chylomicron cascade is regulated by dietary fats. It is our contention that chronically elevated plasma levels of Abeta in response to diets rich in saturated fats may lead to disturbances within the cerebrovasculature and exaggerated blood-to-brain delivery of circulating Abeta, thereby exacerbating amyloidosis. Consistent with this hypothesis we show that enterocytic Abeta is increased concomitant with apolipoprotein B48. Furthermore, cerebral extravasation of immunoglobulin G, a surrogate marker of plasma proteins is observed in a murine model of Alzheimer's disease maintained on a saturated-fat diet and there is diminished expression of occludin within the cerebrovasculature, an endothelial tight junction protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640080     DOI: 10.1016/j.atherosclerosissup.2008.05.010

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  18 in total

1.  Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice.

Authors:  Ryusuke Takechi; Susan Galloway; Menuka Pallebage-Gamarallage; Cheryl Wellington; Russell Johnsen; John Charles Mamo
Journal:  Histochem Cell Biol       Date:  2009-02-19       Impact factor: 4.304

Review 2.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

3.  Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Dharmini C Mehta; Jennifer L Short; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

Review 4.  Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access.

Authors:  Mitchell P McInerney; Jennifer L Short; Joseph A Nicolazzo
Journal:  AAPS J       Date:  2017-05-01       Impact factor: 4.009

5.  Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Authors:  Angela J Hanson; Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Charles W Wilkinson; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Elaine Tsai; Nadia Postupna; Jing Zhang; Johanna Lampe; Suzanne Craft
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

6.  A New Hypothesis for Alzheimer's Disease: The Lipid Invasion Model.

Authors:  Jonathan D'Arcy Rudge
Journal:  J Alzheimers Dis Rep       Date:  2022-03-25

Review 7.  The Role of High Triglycerides Level in Predicting Cognitive Impairment: A Review of Current Evidence.

Authors:  Alina Mihaela Dimache; Delia Lidia Șalaru; Radu Sascău; Cristian Stătescu
Journal:  Nutrients       Date:  2021-06-20       Impact factor: 5.717

8.  Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood-brain barrier function in wild-type mice.

Authors:  Ryusuke Takechi; Menuka M Pallebage-Gamarallage; Virginie Lam; Corey Giles; John C Mamo
Journal:  J Neuroinflammation       Date:  2013-06-19       Impact factor: 8.322

9.  Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation.

Authors:  L M Tai; K A Holloway; D K Male; A J Loughlin; I A Romero
Journal:  J Cell Mol Med       Date:  2009-04-02       Impact factor: 5.310

10.  Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

Authors:  Laura E Donovan; Eric B Dammer; Duc M Duong; John J Hanfelt; Allan I Levey; Nicholas T Seyfried; James J Lah
Journal:  Alzheimers Res Ther       Date:  2013-06-13       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.